To facilitate the clinical testing of seviteronel and dexamethasone (SEVI-D) in combination with docetaxel in androgen receptor (AR) positive triple-negative breast cancer.
Signed written and voluntary informed consent.
Patient must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
Age 18 years or older male or female.
Eastern Cooperative Oncology Group Performance Status of 0 or 1
Inability to comply with study and follow-up procedures.
History of malabsorption syndrome or other condition that would interfere with enteral absorption or results in the inability or unwillingness to swallow pills.
Active infection requiring antibiotics.
Other invasive malignancy within 2 years except for malignancies determined to have low recurrence potential in discussion with study PI.